GlassScriptPhysician profile
Lovelesh Manocha
NPI 1407960552
$3,331.83
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $498 · 2021: $267 · 2022: $698 · 2023: $1,248 · 2024: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $378.31 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $365.21 | 2019-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $305.69 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $277.79 | 2021-2023 | |
| Pfizer INC. | $271.70 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $268.97 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.99 | 2023 | |
| Astellas Pharma US INC | $154.65 | 2019-2021 | |
| Abiomed | $138.27 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $136.97 | 2021-2022 | |
| Penumbra, INC. | $127.28 | 2023 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $121.53 | 2021-2023 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $110.50 | 2020-2022 | |
| Osprey Medical INC | $104.20 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.25 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.73 | 2022-2023 | Otezla, Repatha |
| Altathera Pharmaceuticals LLC | $55.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $50.20 | 2020-2022 | |
| Mannkind Corporation | $35.93 | 2023 | Afrezza |
| Glaxosmithkline, LLC. | $31.75 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.71 | 2021 | |
| Dexcom, INC. | $17.38 | 2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $14.73 | 2021 | |
| Sanofi Pasteur INC. | $14.42 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.11 | 2023 | Cycloset |
| Cequr Corporation | $12.86 | 2022-2023 | Cequr Simplicity |
| Biohaven Pharmaceuticals, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lovelesh Manocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.